Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-κB and inhibition of monocyte chemoattractant protein-1 in urethane-induced lung tumor model

Carcinogenesis

Volumn 33, Issue 12, 2012, Pages 2520-2528

  Lee, Nam Jin ^a   Choi, Dong Young ^a   Song, Ju Kyoung ^a   Jung, Yu Yeon ^a   Kim, Dae Han ^a   Kim, Tae Myung ^a   Kim, Dae Joong ^a   Kwon, Sun Mi ^a   Kim, Kyung Bo ^b   Choi, Kyung Eun ^a   Moon, Dong Cheul ^a   Kim, Youngsoo ^a   Han, Sang Bae ^a   Hong, Jin Tae ^a  

^a Chungbuk National University   (South Korea)

^b University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CHEMOKINE RECEPTOR CCR5; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P50; SMALL INTERFERING RNA; STAT3 PROTEIN; SYNAPTOTAGMIN I; URETHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING KINETICS; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL NUCLEUS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LUNG ADENOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG PARENCHYMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPLEEN; WESTERN BLOTTING; WILD TYPE;

ANIMALS; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL2; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NF-KAPPA B; RECEPTORS, CCR5; STAT3 TRANSCRIPTION FACTOR; URETHANE;

EID: 84870337245     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs265     Document Type: Article

References (55)

1. Wu, X. et al. (2009) Chemokine receptors as targets for cancer therapy. Curr. Pharm. Des., 15, 742-757.
2. Seidl, H. et al. (2007) Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum. Pathol., 38, 768-780.
3. Sutton, A. et al. (2007) Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol. Cancer Res., 5, 21-33.
4. Aldinucci, D. et al. (2008) Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/ Rantes in tumor cell growth and microenvironmental interactions. Int. J. Cancer, 122, 769-776.
5. Erreni, M. et al. (2009) Expression of chemokines and chemokine receptors in human colon cancer. Meth. Enzymol., 460, 105-121.
6. Chuang, J.Y. et al. (2009) CCL5/CCR5 axis promotes the motility of human oral cancer cells. J. Cell. Physiol., 220, 418-426.
7. Valdivia-Silva, J.E. et al. (2009) Effect of pro-inflammatory cytokine stimulation on human breast cancer: implications of chemokine receptor expression in cancer metastasis. Cancer Lett., 283, 176-185.
8. Tan, M.C. et al. (2009) Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J. Immunol., 182, 1746-1755.
9. Ng-Cashin, J. et al. (2003) Host absence of CCR5 potentiates dendritic cell vaccination. J. Immunol., 170, 4201-4208.
10. Zhang, X. et al. (2010) Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents. Bioorg. Med. Chem. Lett., 20, 4627-4630.
11. Borczuk, A.C. et al. (2008) Lung adenocarcinoma invasion in TGFbetaRIIdeficient cells is mediated by CCL5/RANTES. Oncogene, 27, 557-564.
12. Chen, Z. et al. (2001) Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int. J. Cancer, 93, 539-548.
13. Nesbeth, Y.C. et al. (2010) CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J. Immunol., 184, 5654-5662.
14. González-Martín, A. et al. (2011) Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res., 71, 5455-5466.
15. Huang, C.Y. et al. (2009) CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem. Pharmacol., 77, 794-803.
16. Dabaghmanesh, N. et al. (2009) Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. Cancer Sci., 100, 737-746.
17. Shishodia, S. et al. (2004) Nuclear factor-kappaB: a friend or a foe in cancer? Biochem. Pharmacol., 68, 1071-1080.
18. Karin, M. et al. (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer, 2, 301-310.
19. Shukla, S. et al. (2004) Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia, 6, 390-400.
20. Meylan, E. et al. (2009) Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature, 462, 104-107.
21. Pahl, H.L. (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 18, 6853-6866.
22. Gerondakis, S. et al. (1996) Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor. Proc. Natl. Acad. Sci. U.S.A., 93, 3405-3409.
23. Akira, S. et al. (1997) NF-IL6 and NF-kappa B in cytokine gene regulation. Adv. Immunol., 65, 1-46.
24. Cho, M.L. et al. (2006) STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J. Immunol., 176, 5652-5661.
25. Garat, C. et al. (2003) Intracellular IL-1Ra type 1 inhibits IL-1-induced IL-6 and IL-8 production in Caco-2 intestinal epithelial cells through inhibition of p38 mitogen-activated protein kinase and NF-kappaB pathways. Cytokine, 23, 31-40.
26. Schottelius, A.J. et al. (1999) Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J. Biol. Chem., 274, 31868-31874.
27. Chan, K.K. et al. (2010) Interleukin-2 induces NF-kappaB activation through BCL10 and affects its subcellular localization in natural killer lymphoma cells. J. Pathol., 221, 164-174.
28. Jewett, A. et al. (2006) Inhibition of nuclear factor kappa B (NFkappaB) activity in oral tumor cells prevents depletion of NK cells and increases their functional activation. Cancer Immunol. Immunother., 55, 1052-1063.
29. Lin, J. et al. (2002) p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene, 21, 3082-3088.
30. Timofeeva, O.A. et al. (2012) Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. J. Biol. Chem., 287, 14192-14200.
31. Prasad, S. et al. (2010) NF-kappaB and cancer: how intimate is this relationship. Mol. Cell. Biochem., 336, 25-37.
32. Grivennikov, S.I. et al. (2010) Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev., 21, 11-19.
33. Dissanayake, D. et al. (2011) Nuclear factor-κB1 controls the functional maturation of dendritic cells and prevents the activation of autoreactive T cells. Nat. Med., 17, 1663-1667.
34. Dougan, M. et al. (2010) IAP inhibitors enhance co-stimulation to promote tumor immunity. J. Exp. Med., 207, 2195-2206.
35. Lin, Y.L. et al. (2009) An immunomodulatory protein, Ling Zhi-8, induced activation and maturation of human monocyte-derived dendritic cells by the NF-kappaB and MAPK pathways. J. Leukoc. Biol., 86, 877-889.
36. Oh, J.H. et al. (2011) IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. Oncogene, 30, 3345-3359.
37. Song, J.K. et al. (2012) Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-κB and upregulation of IL-1Ra in melanoma model. PLoS ONE, 7, e33747.
38. Langers, I. et al. (2012) Natural killer cells: role in local tumor growth and metastasis. Biologics, 6, 73-82.
39. Kawanami, D. et al. (2011) Thrombin induces MCP-1 expression through Rhokinase and subsequent p38MAPK/NF-κB signaling pathway activation in vascular endothelial cells. Biochem. Biophys. Res. Commun., 411, 798-803.
40. Mou, H.B. et al. (2011) Transforming growth factor-β1 modulates lipopolysaccharide-induced cytokine/chemokine production and inhibits nuclear factor-κB, extracellular signal-regulated kinases and p38 activation in dendritic cells in mice. Transplant. Proc., 43, 2049-2052.
41. Ning, R. et al. (2011) Staphylococcus aureus regulates secretion of interleukin-6 and monocyte chemoattractant protein-1 through activation of nuclear factor kappaB signaling pathway in human osteoblasts. Braz. J. Infect. Dis., 15, 189-194.
42. Ying, W.Z. et al. (2011) Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism. Blood, 117, 1301-1307.
43. Cai, K. et al. (2011) MCP-1 upregulates amylin expression in murine pancreatic β cells through ERK/JNK-AP1 and NF-κB related signaling pathways independent of CCR2. PLoS One, 11, 19559.
44. Miotto, D. et al. (2007) CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer. Respir. Med., 101, 1738-1743.
45. Ji, H. et al. (2006) K-ras activation generates an inflammatory response in lung tumors. Oncogene, 25, 2105-2112.
46. Fridlender, Z.G. et al. (2011) Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am. J. Respir. Cell Mol. Biol., 44, 230-237.
47. Fridlender, Z.G. et al. (2010) CCL2 blockade augments cancer immunotherapy. Cancer Res., 70, 109-118.
48. Dey, A. et al. (2007) Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle, 6, 2178-2185.
49. Tang, C.H. et al. (2012) CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-κB signaling pathway. Biochem. Pharmacol., 83, 335-344.
50. Tan, M.C. et al. (2009) Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J. Immunol., 1, 1746-1755.
51. Stathopoulos, G.P. et al. (2011) Granulocyte colony-stimulating factor expression as a prognostic biomarker in non-small cell lung cancer. Oncol. Rep., 25, 1541-1544.
52. Fukutomi, T. et al. (2012) Pulmonary pleomorphic carcinoma producing granulocyte-macrophage colony-stimulating factor: report of a case. Surg. Today, 42, 288-291.
53. Pollard, J.W. (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer, 4, 71-78.
54. Guthridge, M.A. et al. (2004) The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-kappaB and induction of bcl-2. Blood, 103, 820-827.
55. Kazmierski, W. et al. (2003) Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg. Med. Chem., 11, 2663-2676.